These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 9361721)
1. Minimal doses of hydroxyurea for sickle cell disease. Lima CS; Arruda VR; Costa FF; Saad ST Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721 [TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]
3. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591 [TBL] [Abstract][Full Text] [Related]
4. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628 [TBL] [Abstract][Full Text] [Related]
5. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy. Borba R; Lima CS; Grotto HZ J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630 [TBL] [Abstract][Full Text] [Related]
6. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220 [TBL] [Abstract][Full Text] [Related]
7. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience. Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012 [TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective. Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390 [TBL] [Abstract][Full Text] [Related]
9. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Al-Nood HA; Al-Khawlani MM; Al-Akwa A Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877 [TBL] [Abstract][Full Text] [Related]
10. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586 [TBL] [Abstract][Full Text] [Related]
11. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Saleh AW; Hillen HF; Duits AJ Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885 [TBL] [Abstract][Full Text] [Related]
12. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115 [TBL] [Abstract][Full Text] [Related]
13. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Charache S Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197 [TBL] [Abstract][Full Text] [Related]
15. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171 [TBL] [Abstract][Full Text] [Related]
16. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375 [TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia. Keikhaei B; Yousefi H; Bahadoram M Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428 [TBL] [Abstract][Full Text] [Related]
18. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Ballas SK; Marcolina MJ; Dover GJ; Barton FB Br J Haematol; 1999 May; 105(2):491-6. PubMed ID: 10233426 [TBL] [Abstract][Full Text] [Related]
19. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin. el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719 [TBL] [Abstract][Full Text] [Related]
20. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]